HLN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

2.81B

+1.7%

0.000

-100%

Estimates Revision

The market is revising Upward the revenue expectations for Haleon plc (HLN) for FY2025, with the revenue forecasts being adjusted by 0.5% over the past three months. During the same period, the stock price has changed by 4.79%.

Revenue Estimates for FY2025

Revise Upward

+0.5%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.54%

In Past 3 Month

Stock Price

Go Up

+4.79%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is 13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 9.850

Low

13.44

Averages

13.44

High

13.44

Current: 9.850

Low

13.44

Averages

13.44

High

13.44

Morgan Stanley

Rashad Kawan

maintain

2025-12-15

New

Reason

Morgan Stanley

Rashad Kawan

Price Target

2025-12-15

New

maintain

Reason

Morgan Stanley analyst Rashad Kawan raised the firm's price target on Haleon to 420 GBp from 400 GBp and keeps an Overweight rating on the shares.

Berenberg

Bethan Davies

Buy

maintain

2025-11-07

Reason

Berenberg

Bethan Davies

Price Target

2025-11-07

maintain

Buy

Reason

Berenberg analyst Bethan Davies raised the firm's price target on Haleon to 517 GBp from 507 GBp and keeps a Buy rating on the shares.

Barclays

Overweight -> Equal Weight

downgrade

2025-09-16

Reason

Barclays

Price Target

2025-09-16

downgrade

Overweight -> Equal Weight

Reason

Barclays downgraded Haleon to Equal Weight from Overweight with a price target of 380 GBp, down from 430 GBp. The U.S. represents 34% of the company's sales and is seeing slower category growth and destocking, the analyst tells investors in a research note. The firm says Haleon has overweight exposure to declining U.S. drug stores. The company cut its 2025 outlook but there remains short-term risks, contends Barclays. It moves to the sidelines pending a plan from Haleon's new U.S. head.

Goldman Sachs

Olivier Nicolai

Neutral -> Buy

upgrade

£440

2025-09-10

Reason

Goldman Sachs

Olivier Nicolai

Price Target

£440

2025-09-10

upgrade

Neutral -> Buy

Reason

Goldman Sachs analyst Olivier Nicolai upgraded Haleon to Buy from Neutral with a 440 GBp price target. The firm sees the company's fundamentals inflecting in fiscal 2026 due to stronger volume, a U.S. recovery and ongoing high-single-digit Oral Health growth. With Haleon's organic sales growth positioned to accelerate into 2026, the shares are trading at an attractive entry point, the analyst tells investors in a research note.

Berenberg

Bethan Davies

Buy

downgrade

2025-08-12

Reason

Berenberg

Bethan Davies

Price Target

2025-08-12

downgrade

Buy

Reason

Berenberg analyst Bethan Davies lowered the firm's price target on Haleon to 500 GBp from 503 GBp and keeps a Buy rating on the shares.

Barclays

Overweight

NULL

downgrade

$475 -> $450

2025-07-08

Reason

Barclays

Price Target

$475 -> $450

2025-07-08

downgrade

Overweight

NULL

Reason

Barclays lowered the firm's price target on Haleon to 450 GBp from 475 GBp and keeps an Overweight rating on the shares.

Valuation Metrics

The current forward P/E ratio for Haleon PLC (HLN.N) is 0.00, compared to its 5-year average forward P/E of 15.35. For a more detailed relative valuation and DCF analysis to assess Haleon PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

15.35

Current PE

0.00

Overvalued PE

22.42

Undervalued PE

8.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.98

Current EV/EBITDA

14.17

Overvalued EV/EBITDA

14.87

Undervalued EV/EBITDA

13.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.73

Current PS

2.89

Overvalued PS

2.98

Undervalued PS

2.48

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 142.48% over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased100%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HLN News & Events

Events Timeline

No data

News

2.0

12-12Newsfilter

Haleon Recognized in Fast Company's 2025 Brands That Matter for Consumer Trust

2.0

12-12Businesswire

Haleon Recognized in Fast Company’s 2025 Brands That Matter List

4.5

12-09NASDAQ.COM

Unusual Volume Noted for QLTI ETF on Tuesday

People Also Watch

Frequently Asked Questions

What is Haleon PLC (HLN) stock price today?

The current price of HLN is 9.85 USD — it has increased 0.2 % in the last trading day.

What is Haleon PLC (HLN)'s business?

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

What is the price predicton of HLN Stock?

What is Haleon PLC (HLN)'s revenue for the last quarter?

Haleon PLC revenue for the last quarter amounts to 2.63B USD, decreased -5.33 % YoY.

What is Haleon PLC (HLN)'s earnings per share (EPS) for the last quarter?

Haleon PLC. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Haleon PLC (HLN)'s fundamentals?

How many employees does Haleon PLC (HLN). have?

Haleon PLC (HLN) has 24622 emplpoyees as of December 17 2025.

What is Haleon PLC (HLN) market cap?

Today HLN has the market capitalization of 43.86B USD.